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Abstract
Background: Lymphatic filariasis elimination programs are based upon preventative chemotherapy annually in
populations with prevalence more than or equal to 1%. The goal is to treat 80% of the eligible, at risk population
yearly, for at least 5 years, in order to interrupt transmission and prevent children from becoming infected. This
level of coverage has been a challenge in urban settings. Assessing the coverage in a rapidly growing urban/non-
rural setting with inadequate population data is also problematic. In Sierra Leone, a 5-day preventative
chemotherapy campaign was carried out in the Western Area including the capital: Freetown. An intensive, social
mobilization strategy combined traditional and modern communication channels. To aid dissemination of
appropriate information Frequently Asked Questions were developed and widely circulated. The population of the
Western Area has grown faster than projected by the 2004 National Census due to the post-war settlement of
internally displaced persons. As a reliable denominator was not available, independent monitoring was adapted
and performed “in process” to aid program performance and “end process” to assess final coverage.
Results: In 5 days 1,104,407 eligible persons were treated. Using the projected population from the 2004 census
this figure represented coverage of 116% in the Urban Western Area and 129% in the Rural Western Area.
Independent monitors interviewed a total of 9,253 persons during the 2 End Process days representing 1% of the
projected population. Of these, 85.8% recalled taking both ivermectin and albendazole (Urban: 85.2%, Rural: 87.1%).
No serious adverse drug reactions were reported.
Conclusion: The paper presents the key elements of success of the social mobilization and implementation
strategy and describes the independent monitoring used to estimate final coverage in this urban/non-rural setting
where the current population size is uncertain. This implementation strategy and Independent Monitoring tool
could be useful in similar, rapidly growing cities implementing lymphatic filariasis elimination programs.
Background
Preventative chemotherapy and transmission control
(PCT) with albendazole and ivermectin (or diethylcarba-
mazine) annually in populations ‘at risk’ where lympha-
tic filariasis (LF) prevalence of ≥1% is the basis of LF
elimination programs [1]. The goal is to treat at least
80% of the eligible, at risk population yearly, for at least
5 years, in order to interrupt transmission of LF by
making the infectious microfilaria (MF) stages
unavailable to the mosquito vectors [2]. Pregnant
women, the unwell and children under five years are
not eligible for treatment. This ultimately leads to elimi-
nation when MF falls to less than 1% in many commu-
nities especially in areas where Anopheles mosquitoes
are the main vectors. In Sierra Leone, the prevalence of
LF by immuno-chromatographic tests (ICT) was found
to be 23% overall, and it was 7% in the Rural Western
Area (RWA) and 12% Urban Western Area (UWA): the
capital Freetown [3]. The UWA and RWA are politically
defined administrative areas. Although the RWA has
many rural villages, there are some areas with piped
water and electricity. Similarly in the UWA, there are
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any medium, provided the original work is properly cited.many areas still with typical rural characteristics. There-
fore these areas are best described as non-rural.
The national LF elimination program evolved from the
national onchocerciasis control program in 2007 by add-
ing albendazole to the Community Directed Treatment
with Ivermectin (CDTI) to become Community Directed
Treatment with Ivermectin plus Albendazole (CDTI+).
Normally CDTI+ is performed by community volunteers
after they have taken a “village census” and takes
6-8 weeks to complete. The national LF elimination pro-
gram scaled up geographical coverage to include all
districts excluding the UWA in 2008.
In the RWA, CDTI+ was conducted in 2008 but poor
coverage achieved: 22.7% (Kamara et al. unpublished
data). This poor coverage illustrated that many parts of
the RWA may no longer be “rural” due to the mass
influx of internally displaced persons during the recent
war 1991-2002, who have since settled there. The poor
coverage also illustrated the difficulty in implementing
CDTI+ in non-rural settings as reported by other coun-
tries [4-7]. Effective social mobilization and awareness of
LF are known to be the key to improved coverage for LF
elimination programs [8,9]. The implementation of
CDTI+ in the RWA, 2008 also highlighted the difficulty
in implementing CDTI+ with community volunteers
(un-paid) in non-rural settings.
The National Neglected Tropical Disease (NTD) Task
Force decided to change strategy in the UWA and RWA
and utilize a modification of the National Immunization
Day (NID) strategy for 2010 and scheduled 5 day imple-
mentation by paid community health workers in a street
by street and fixed health center distribution campaign.
Recent experience in Sierra Leone with multiple NID
campaigns against measles, polio (4 rounds) and yellow
fever have strengthened the administrative links between
District Health Management Teams (DHMT), their per-
ipheral health units (PHUs) and in turn an extensive
network of community health workers (CHWs). Build-
ing on lessons learned the LF-campaign was synchro-
nized to occur immediatelyf o l l o w i n gt h eM o t h e ra n d
Child Health Week so that the same peripheral health
personnel, CHWs and channels of communication
could be used to disseminate information and materials
to peripheral health units and onwards to their catch-
ment communities.
The objective was to administer ivermectin and alben-
dazole to a minimum of 80% of the eligible WA popula-
tion. The actual populations of the UWA and RWA are
greater than the 2004 Census projections due to the
large influx of internally displaced persons during and
after the war. As no pre-intervention census was under-
taken, independent monitoring was implemented to
assess the final coverage. This paper reports on the
implementation strategy, social mobilization, the high
coverage achieved in the UWA and RWA, and relative
cost needed for each person treated.
Methods
Information, education and communication (IEC)
Suitable IEC material for the urban and semi-urban setting
was developed by the NTD Task Force and pre-tested.
Frequently Asked Questions (FAQs) were developed to
ensure that appropriate, consistent and culturally sensitive
messages about LF, the NID campaign and exclusion cri-
teria were disseminated to the health sector and wider
public to minimize misinformation. The FAQs were
repeatedly tested, improved, and disseminated in the
2 week pre-campaign launch responding to public feed-
back from community meetings, phone-ins or SMS mes-
sages following radio discussions. These FAQs clearly
explained to leaders the participation expected of them to
facilitate the campaign such as the provision of drinking
water within their communities. As the low income and
very-low income populations are known to be most at risk
of Wuchereria bancrofti microfilaraemia [10] special
emphasis was given in the FAQs requesting the more lit-
erate to inform vulnerable groups in their neighborhoods
and workplaces and to explain to them how to access
treatment during the campaign.
New posters of a ‘PCT image’ and a ‘Tag’ were devel-
oped and pre-tested to suit the urban context where
higher literacy rates suggested that a more critical atti-
tude towards PCT would be encountered. The ‘Tag’ in
the local language emphasized that the medicines were
free of charge and treated “worrums” as well as “bigfut”,
the local names for STHs and LF. The new ‘PCT image’
graphically explained the treatment protocol, illustrating
ad o s ep o l ea n df a m i l ym e m b e r sr e c e i v i n gd i f f e r e n t
dosages of ivermectin plus one albendazole (figure 1).
The ‘PCT image and Tag’ was reproduced in A4 lami-
nated cards so that all councilors, PHU staff, CHWs,
zonal supervisors and independent monitors could refer
Figure 1
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Tag’ was advertised in a leading newspaper for the dura-
tion of the campaign together with an editorial on the
first day.
Social mobilization
Social mobilization was intense, coordinated and com-
prehensive over a 3-week period. A full-day advocacy
meeting was held by the District Health Management
Team-Western Area (DHMT-WA) which explained the
justification for the LF campaign, the disease, implemen-
tation strategy, exclusion criteria, target priorities and
time-line in order to solicit the full cooperation of senior
leaders. All community radio stations were supplied
copies of an interview based upon the FAQs and addi-
tional radio discussions, jingles and spot messages for
broadcasting the week prior and during the campaign.
This enabled an interactive platform with the public via
phone-ins and SMS messages to address misunderstand-
ings regarding “bigfut”. The public’sm o s tf r e q u e n tc o n -
cern related to traditional beliefs and witchcraft. The
Director of Education, Western Area notified all schools
of this campaign in advance allowing head teachers time
to inform parents and obtain consent for the CHWs to
enter schools and treat children. The key elements of
social mobilization are shown in Appendix 1.
Reporting
Reporting forms had been simplified from the CDTI+
returns. Tally sheets were developed that required only
the recipient’s sex, the number of ivermectin tablets
administered and the total of ivemectin and albendazole
dispensed by that CHW team on a single day. The dis-
tribution of CHWs per PHU was based upon the size of
the PHU catchment area and previous NID experience
of the ‘Hard to Reach’ areas. Each CHW team was esti-
mated to need to treat approximately 218 persons daily
to reach all eligible persons. A total of 1,030,000 doses
was initially allocated prior to the launch. Summary
sheets were made in each of the 120 PHUs, compiled by
the zonal supervisors for daily de-briefing with the
DHMT-WA and independent monitors at the end of
the day.
Training
Training of health service supervisors following the
advocacy meeting enabled each of the 120 health units
in the WA to hold a community meeting in participa-
tion with civil, traditional and religious leaders in their
catchment areas. At these meetings the FAQs were used
to guide discussion and provide satisfactory answers to
often challenging questions. Training by the PHU super-
visors of 1,700 Community Health Workers (CHWs)
was performed the day before the commencement of
the PCT campaign. This rapid training-implementation
strategy had been found successful in the previous schsi-
tosomiasis campaign in June 2009 (Hodges et al. unpub-
lished data). Strict adherence to a training agenda using
the LF Training Manual and FAQs were followed by
practice using dose poles and tally sheets to ensure con-
sistency of best practice throughout the WA.
Implementation
Implementation was performed by CHWs working in
teams of two (a total of 850 teams): one to recruit, orga-
nize and measure the height of participants and the
other to record and dispense drugs by directly observed
treatment. A launching ceremony filmed by National
Television crews and broadcast that evening targeted
the “middle classes” who witnessed senior medical and
political figures participating in “directly observed treat-
ment”. The Thursday launch enabled CHWs to access
all schools and colleges before the weekend, the children
then sensitized their parents further when they returned
home from school. Prisons, army, council workers
(street cleaners) and police barracks were early institu-
tions reached on days 1-2. Street by street coverage was
performed from day 1. The mosques were attended by
CHWs after prayers on Friday (day 2) and churches on
Sunday (day 4). By Monday (day 5) the more ‘sophisti-
cated” commercial areas were targeted together with
“mopping up” of areas less well covered that had been
identified by personal contacts, monitors or supervisors.
The key elements of implementation are shown in
Appendix 2.
Although the initial distribution of drugs was in excess
of that calculated to reach 80% of eligible population pro-
jections (1,030,000 versus 743,025) by campaign day 2 it
was evident that more drugs would be required to meet
the need. Additional supplies were sourced by the
NTDCP from the provinces and by a donation from a
local NGO that enabled health units to be re-stocked
during Day 3 enabling PCT to continue for Days 4 and 5.
Independent Monitoring
The existing population data based upon normal growth
from the National Census 2004 was not considered a
reliable denominator to assess final coverage. Commu-
nity Drug Distributors have been used to carry out cen-
sus in urban settings prior to commencement of CDTI
in other countries, however, this was not considered fea-
sible in the UWA and RWA due to the size and transi-
ent nature of the populations in many of these new
post-conflict settlements. Therefore, independent moni-
toring was used to evaluate the coverage.
Independent monitoring developed for the recent
polio campaigns by the WHO was adapted for the LF
campaign using a cluster sampling method stratified by
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tion areas (EAs): collections of households (defined as a
group of people who eat from the same cooking pot)
grouped within defined administrative boundaries from
the 2004 census. The list of EAs was used for the selec-
tion of the 30 clusters using probability proportional to
size (PPS) for RWA and for UWA. The clusters were
physically located by the independent monitors.
Twenty independent monitors were trained for one
day and worked from days 3-5 of the PCT campaign
with in-process monitoring and two days of end-process
monitoring. Five communal “locations” in each site were
sampled representing placess u c ha sb u ss t o p s ,l o c a l
markets, school environs, churches or mosques, petrol
stations, shops, farms, workshops, entertainments cen-
ters or street water pumps. A minimum of 30 and a
maximum of 50 people were interviewed in each loca-
tion depending upon the size of the location and asked
whether they had taken ivermectin and albendazole
prompted by the ‘PCT image and Tag’ if needed.
In addition the monitors walked 10 and 20 minutes
away from the nearest health center in UWA and RWA
respectively to reach the periphery of that catchment
area without entering the next catchment area where
they sampled a minimum of 30 and a maximum of
50 households. The first household was selected from a
house representative of the locality; the second house-
hold was the one that was immediately on right of the
previous household and so on. In each household the
monitors distributed numbered ballot cards to “eligible”
persons. A number was then randomly selected and the
person with that number on the card was interviewed
and the recall of that single respondent was recorded. If
only one person in the house and is eligible then that
person is interviewed.
On the last day of “In Process” monitoring and the
Day 2 of “End Process” monitoring 30 “Hard to Reach”
areas were monitored in UWA and also in RWA.
Statistical Analysis
The data from the independent monitoring was ana-
lyzed by Chi-squared (c
2) test to determine significant
difference of final coverage results between RWA,
UWA, Day 1 ‘End process’ and Day 2 ‘End process,
Hard to Reach’, Household or communal location at 5%
level of confidence.
Cost analysis
The costs of the PCT in the WA were analysed, and
included those for social mobilization, production of
IEC materials, radio broadcasts, press releases, newspa-
per advertisements, launching ceremony, training and
allowances for CHWs and independent monitors, and
supervisions by program teams. A simple cost per
person treated was calculated using these costs and the
total number of persons treated. The costs did not
include all running costs for the Ministry of Health and
Sanitation program staff and DHMT staff, such as sal-
aries, benefits, office and vehicle expenditures. The costs
for drugs were also not included in the calculation as
both ivermectin and albendazole are donated by Merck
and GlaxoSmithKline respectively.
Results
Using the projected data from the national census [11]
the total population of the WA is 1,187,460 (UWA:
945,501, RWA: 241,959) and the eligible population
(excluding pregnant women, children under 5 years and
the unwell) was estimated as WA 928,781 (UWA:
740,328, RWA: 188,453) as shown in Table 1.
Results based upon the Population Census and DHMT
records of treatments performed
The results based upon the projected eligible population
from the 2004 census and the daily compilation of tallies
is shown in Table 1. By Day 1, 46% of the eligible popula-
tion had received treatment and by Day 2: 80%, Day 3:
9 9 % ,D a y4 :1 0 9 %a n dD a y5 :1 1 9 %c o v e r a g eh a db e e n
achieved. The total tally of persons treated over the 5 day
campaign was 1,104,407 (UWA: 861,024, RWA: 243,383).
Using these records 116% of the eligible population had
been treated in the UWA and 129% in the RWA.
Results based upon the Independent Monitoring
The “in process” independent monitoring started on
campaign day 3 and showed that 72.5% interviewees
(3268/4510) on Day 3, 79.5% (3674/4622) on Day 4 and
84.9% (3398/4003) on Day 5 recalled taking both iver-
mectin and albendazole. The results of the 2 days of
end process independent monitoring are summarized in
T a b l e2 .T h es a m p l es i z eo ft h o s ei n t e r v i e w e dr e p r e -
sented 1.00% of the eligible target population (UWA:
0.86%, RWA: 1.55%) and represented 0.84% of the per-
sons treated (UWA: 0.74%, RWA: 1.20%).
A total of 9249 eligible persons (UWA: 6337, RWA:
2912), were interviewed in the 2 combined “End Pro-
cess” days. Of these 7933 persons recalled taking both
ivermectin and albendazole (UWA: 5396, RWA: 2537)
equivalent to 85.9% final coverage (Urban WA: 85.2%,
Rural WA: 87.1%). There was a significant difference in
coverage amongst persons interviewed in households in
UWA versus both those interviewed on location at End
process in UWA and versus those interviewed on loca-
tion at End process in RWA (p < 0.005). There was no
significant difference in coverage between those inter-
viewed at home versus location in the RWA (p = 0.72).
There was no significant difference in coverage amongst
persons interviewed at End Process Day 1 versus Day 2:
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RWA (p = 0.58). There was a significant difference in
overall coverage at End process in UWA versus RWA
(p < 0.05).
Severe Adverse Reactions
No serious adverse events were formally reported to the
Pharmacy Board by the PHU staff. One person with
severe vomiting on Tasso Island had required oral rehy-
dration and then intravenous rehydration was informally
reported. There were 146 minor drug reaction reporting
238 symptoms (males 126: females: 110) mostly itching:
79, swelling: 59, rashes: 25, headache: 16, dizziness: 13,
abdominal discomfort: 10 and vomiting: 9 lasting less
than 3 days. Reports of polyuria (6), erectile dysfunction
(3) and numbness of the limbs (1) were made not pre-
viously reported in the literature.
Cost
This NID campaign cost $132,000 including the inde-
pendent monitoring but excluding standing costs for the
NTDCP, DHMT-WA and drugs. This represents $0.12
per person treated.
Discussion
The challenge of obtaining high coverage in urban set-
tings has been reported in Orissa: 42% [4], Haiti: 68.3%
[5], Columbo: 53.4% [6] and Tamil Nadu 73% [7]. Using
the 2004 census projections, PCT coverage in the UWA
would have been reported as 116%, while using indepen-
dent monitoring data, PCT coverage was 85.2%. Like-
wise the RWA would have been reported as 129% based
upon census projections while it was 87.1% by indepen-
dent monitoring. The disparity is a reflection of the
population growth in the WA since 2004 due to the
post war settlement, especially so for the RWA which is
now a rapidly growing non-rural setting in many parts.
The coverage was remarkably higher compared with
22.7% in the previous CDTI+ performed in the RWA,
2008 (Kamara et al. unpublished data) and with 72.9%
in the other 12 Districts of Sierra Leone achieved in the
last round of CDTI+, 2009.
The remarkable improvement in coverage from 22.7%
with CDTI+ in 2008 to 87.1% with this NID strategy in
the RWA may also be a reflection of increased human
resource capacity within the health sector following the
Government of Sierra Leone launch of Free Health care
in 2010 and considerable investments from other donors
since the end of the war. In addition the recent Yellow
fever campaign in December 2009 and 4 polio cam-
paigns March-May 2010 had strengthened the DHMT-
WA their administrative structures, data sources and
communication links with their PHU staff and CHWs
making them “campaign ready”. Motivating CHWs with
a small daily remuneration over a short time-frame was
also highly appreciated and improved their performance.
Although there was a significantly lower overall cover-
age of those interviewed in household in the UWA
Table 1 Reported ivermectin and albendazole treatments by area, day and cumulative coverage (%) by projected
eligible population (National Populations Census 2004)
Projected Pop Projected Eligible Pop Day 1 Day 2 Day 3 Day 4 Day 5 Day 1-5
Area Treated % Treated % Treated % Treated % Treated % Treated
UWA 945,501 740,327 341,194 46 253,401 80 134,555 98 64,896 107 66,978 116 861,024
RWA 241,959 188,454 86,653 46 63,836 80 40,521 101 27,047 116 25,326 129 243,383
Total 1,187,460 928,781 427,847 46 317,237 80 175,076 99 91,943 109 92,304 119 1,104,407
Table 2 Number of persons interviewed by Household or by Location and recalling taking both ivermectin and
albendazole by area, day and compliance (%) for Day 1 and Day 2 End Process
Sample size as % of
treatments
Sample size as % of
eligible pop
Day 1: End Process Day 2 End Process:
Hard to Reach
Total Day 1 & 2: End
Process
UWA Interview Recall % Interview Recall % Interview Recall %
Household 460 371 80.7 530 418 78.9 990 789 79.7
Location 2734 2332 85.3 2613 2275 87.1 5347 4607 86.2
Subtotal 0.74% 0.86% 3194 2703 84.6 3143 2693 85.7 6337 5396 85.2
RWA
Household 267 236 88.4 281 244 86.8 548 480 87.6
Location 1056 907 85.9 1308 1150 87.9 2364 2057 87.0
Subtotal 1.20% 1.55% 1323 1143 86.4 1589 1394 87.7 2912 2537 87.1
Total 0.84% 1.00% 4517 3846 85.1 4732 4087 86.4 9249 7933 85.8
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in locations in the RWA the final coverage was still as
high as 79.5%. There was no significant difference in
coverage amongst those interviewed on the ‘End pro-
cess’ Day 1 and Day 2 in the ‘Hard to Reach’ areas
although the lowest coverage was 78.9% in households
in the ‘Hard to reach”, UWA.
The more “modern” approaches to community sensiti-
zation such as the recurrent distribution of FAQs by
community radios and internet reached individuals and
institutions throughout Sierra Leone that had been una-
ware of CDTI+ through more “traditional” methods.
There might have been some internal migration into the
WA in order to receive PCT during these 5 days
because of the high visibility of this campaign but these
individuals would probably not have been represented in
the 2 days End Process monitoring as they would have
returned to their districts.
The interactive use of community radio with follow-up
discussions based upon phone-in questions and SMS
messages together with the extension, intensive social
mobilization by all PHU staff in collaboration with tradi-
tional, religious and council leaders enabled feedback to
the NTDCP and rapid revision of the FAQs. This led to a
much better understanding of the current concerns and
beliefs of the urban/non-rural population and potential
challenges during the campaign in time for these to be
addressed during the training of the CHWs the day
before PCT implementation commenced. The hand-held
PCT image and Tag facilitated the discussion by the
CHWs within the communities during implementation.
The pharmacovigilance teams received no reports of
serious adverse effects from the PHU staff during the
campaign although polyuria, erectile dysfunction and
numbness of the limbs were reported. Despite achieving
such high coverage there are still lessons to be learnt.
Most notable was the perception amongst the young
adults that ivermectin and albendazole might have an
adverse effect upon fertility or potency. In addition the
influx of individuals into non-rural setting for treatment
during a highly visible campaign could be anticipated
even where PCT has been implemented in the sur-
rounding provinces and a reserve of drug stocks made
available to avoid loss of momentum. Cinemas, tele-cen-
ters and sports clubs could be included as distribution
points in future campaigns. Some household members
waited at home for treatment even when they were
aware of the CHWs distribution in their street locations.
The explanation that the distribution of drugs for the
LF campaign is not strictly house to house but street by
street will require further attention in the FAQs in
future campaigns.
The calculation of the eligible population was based
upon the current estimates of 18% of the total
population being under 5 years of age and 4% being
either pregnant or unwell. As 1,104,407 doses were
required to reach 85.8% of the eligible population of the
WA the total population in the WA can be estimated as
approximately 1,650,790. Since the 2004 census pro-
jected population for the WA in 2010 was 1,186,183 this
would represent an additional 464,607 persons and a
growth of 39% above projections.
The cost of this LF campaign at 0.12 USD per person
achieving 85.2% in the UWA including social mobiliza-
tion and implementation with paid community health
workers compares favorably with COMBI (++) used in
Tamil Nadu that achieved 73% coverage [9].
Whilst the weaknesses of the method of Independent
Monitoring are well recognized by the authors it was
affordable, quick, and simpl ea n dp r o v i d e dv a l u a b l e
information: final WA coverage estimate of 85.8% which
would not have been obtainable from the normal
reporting procedures based upon the projected popula-
tion data.
Conclusion
This NID campaign for PCT-LF with its short time
frame and high visibility c o u l db eu t i l i z e db yo t h e r
countries implementing LF control in urban settings.
The high coverage was achieved by coordinated, intense,
focused social mobilization using traditional and modern
strategies. The use of Frequently Asked Questions
adapted and modified in the local context before and
during the campaign ensured that consistent “best prac-
tice” was being followed by all involved. The ‘PCT
image and Tag’ adapted for the urban context mini-
mized the problems of communication between CHWs
and a public unfamiliar with dose poles, protocols and
ivermectin. Independent Monitoring enabled an end
process coverage figure to be reported and is recom-
mended in similar, urban/semi-urban settings for LF
elimination programs where the population is rapidly
growing and accurate census projections unavailable.
Appendix 1: Key points to successful Social
Mobilization: Adapted IEC materials
Posters with ‘PCT Image and Tag’ to explain dosage,
diseases and free of charge protocol
Revised ‘PCT Image and Tag’ carried by all CHWs to
help explain dosage protocol
A d v o c a c ym e e t i n g sf o rs e n i o rl e a d e r sl e a db yt h eD i s -
trict Health Management Team-WA including
Councilors from Freetown City Council, Western Area
Rural District Council, civil society, Interreligious Coun-
cil, tribal leadership council
Letters to Parliamentarians, Medical and Nursing pro-
fession, Private medical practitioners, Labor Unions and
Director of Education-WA
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Unit following the ‘FAQs script’ for consistency of
information
Community Radio broadcasting of discussions follow-
ing the ‘FAQs script’ in the 2 weeks prior to the
campaign
Internet circulation of repeatedly revised FAQs by
email and finally Facebook to all contacts within the
WA not just the health sector
Presentation of plans to all NGOs in two monthly
meetings leading up to and including the launch day
Newspaper articles and advertisement with ‘PCT
Image and Tag’
Press Conferences at Ministry of Information and
Communication attended by SL national journalists
association
National Television broadcasts of the Campaign
launch and progress during the campaign
Appendix 2: Key point to successful
implementation
Information sharing, early discussions and collaboration
by the DHMT-WA with other stakeholders
Strong Management, planning, commitment and co-
ordination by the DHMT
Capacity within the Health Sector due to increased
personnel and training
Technical support from Helen Keller International
Country Office developing IEC materials
Structured cascade Training of PHU and CHWs fol-
lowing the FAQs and LF Training Manual
Recent revised pay structure within the health sector
and increased number of peripheral unit staff
Experienced National and Zonal Supervisors
Adequate and timely funding from USAID through
RTI
Synchronization with the Mother and Child Health
Week to assist communication and supplies
Motivation of the Health Sector: payment of incen-
tives by the DHMT upon receipt of reports
Campaign experience following the recent Yellow
Fever and 4 rounds of Polio campaigns
Daily 5 pm de-briefing at the DHMT attended by
Zonal Supervisors and Independent Monitors
Good cooperation between the DHMT, National NTD
Control Program and a local NGO to avert stock outs
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